SLC6A15 作为一种肿瘤抑制因子，可抑制人甲状腺乳头状癌细胞的迁移和侵袭。
SLC6A15 acts as a tumor suppressor to inhibit migration and invasion in human papillary thyroid cancer.
机构信息
Department of Endocrinology and Diabetes Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
出版信息
J Cell Biochem. 2021 Aug;122(8):814-826. doi: 10.1002/jcb.29914. Epub 2021 Mar 10.
Solute Carrier Family 6 Member 15 (SLC6A15), a sodium-dependent neutral amino acid transporter, has been found with dysregulated expression in several kinds of cancers. However, the expression pattern and the biological functions of SLC6A15 in papillary thyroid cancer (PTC) remain unknown. In this study, we found that SLC6A15 was downregulated in PTC, which was related to N classification. Ectopic overexpression of SLC6A15 impaired migratory and invasive abilities of PTC cell in vitro. In addition, we identified intercellular adhesion molecule-1, a vital oncogene in thyroid cancer progression, was involved in the effects of SLC6A15 on PTC cell. These results indicate that SLC6A15 acts as a tumor suppressor and might be a potential therapeutic target in the treatment of PTC.
溶质载体家族 6 成员 15（SLC6A15）是一种钠依赖性中性氨基酸转运体，已在多种癌症中发现其表达失调。然而，SLC6A15 在甲状腺乳头状癌（PTC）中的表达模式和生物学功能仍不清楚。在这项研究中，我们发现 SLC6A15 在 PTC 中下调，这与 N 分类有关。SLC6A15 的异位过表达可损害 PTC 细胞的体外迁移和侵袭能力。此外，我们确定细胞间黏附分子-1（ICAM-1）是甲状腺癌进展中的一个重要癌基因，参与了 SLC6A15 对 PTC 细胞的作用。这些结果表明 SLC6A15 作为一种肿瘤抑制因子，可能是 PTC 治疗的潜在治疗靶点。
Zotero 插件